This study aimed at assessing measurement properties for 3L and 5L in eight broad patient groups. A student cohort was added in order to investigate how both instruments perform in a healthy population sample. Respondents completed both the 3L and 5L in six countries: Denmark, England, Italy, the Netherlands, Poland, and Scotland. Data collection in Denmark was conducted through the endocrinology, rheumatology, and orthopedic departments of a regional university hospital. Data collection in England was organized through a specialist patient recruitment agency and aimed at patients with prespecified conditions. In Italy the cohort of liver disease patients completed the questionnaires locally at two hospitals (Bergamo and Naples). Data collection in the Netherlands was conducted at a specialist center for personality disorders and at a local hospital for the kidney dialysis patients. In Poland, the student cohort was recruited at the Medical University of Warsaw in Poland, and the stroke cohort was recruited through the Neurological Clinic in Warsaw. Data collection in Scotland took place through a specialist patient recruitment agency, with patients completing the questionnaires at primary care centers. Paper and pencil versions of the questionnaires were used in all countries except in England where data collection took place online. Data collection took place between August 2009 and September 2010. The 5L was administered first, followed by the EQ-5D visual analogue scale (EQ-VAS) and a number of demographic questions, then the 3L, and finally a set of five dimension-specific rating scales. All respondents scored 5L first, as a previous study showed a tendency to avoid the in-between levels 2 and 4 of 5L when responding to the 3L first [20 (link)]. Data collection was undertaken with informed consent and according to the ethical guidelines for health research in each country.
>
Disorders
>
Mental or Behavioral Dysfunction
>
Personality Disorders
Personality Disorders
Personality Disorders are a group of mental health conditions characterized by inflexible and maladaptive patterns of thought, emotion, and behavior that deviate from cultural expectations.
These disorders can significantly impair an individual's ability to function in social, occupational, and personal relationships.
Effective research and treatment of Personality Disorders is crucial for improving quality of life and reducing the burden on individuals, families, and healthcare systems.
PubCompare.ai can help optimize your Personality Disorders research by locating the best protocols from literature, preprints, and patents using AI-driven comparisons to enhance reproducbility and accuracy.
Leverage our tool to identify the most effective products and protocols for your Personality Disorders studies and experiecnce the power of data-driven insights today.
These disorders can significantly impair an individual's ability to function in social, occupational, and personal relationships.
Effective research and treatment of Personality Disorders is crucial for improving quality of life and reducing the burden on individuals, families, and healthcare systems.
PubCompare.ai can help optimize your Personality Disorders research by locating the best protocols from literature, preprints, and patents using AI-driven comparisons to enhance reproducbility and accuracy.
Leverage our tool to identify the most effective products and protocols for your Personality Disorders studies and experiecnce the power of data-driven insights today.
Most cited protocols related to «Personality Disorders»
Cerebrovascular Accident
Hemodialysis
Liver Diseases
Patients
Personality Disorders
Population Health
Primary Health Care
Student
System, Endocrine
Visual Analog Pain Scale
42 Dutch patients were clinically assessed using a standard psychiatric interview by five psychiatrists experienced in obsessive-compulsive spectrum disorders. The general medical history as well as the psychiatric history was collected for all patients. Personality pathology was evaluated using the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) [6] . The following questionnaires were completed:
The Hamilton Depression Rating Scale (HAM-D) [7] (link), a 17-item scale determining a patient’s level of depression.
The 14-item Hamilton Anxiety Rating Scale (HAM-A) [8] (link), which measures the severity of anxiety symptoms.
The Symptom Checklist (SCL-90) [9] (link), which is a widely used screening instrument for mental and physical dysfunctioning. The 90 items comprise eight subscales: Agoraphobia, Anxiety, Depression, Somatic complaints, Insufficiency in thinking and acting, Suspicion and interpersonal sensitivity, Hostility and Sleep problems. The total score is seen as a general index for psychoneuroticism.
To measure the severity of the misophonia symptoms, we developed an adapted version of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [10] (link), [11] (link), which we have named the Amsterdam Misophonia Scale (A-MISO-S). Similar adaptations of the Y-BOCS have appeared to be reliable and valid measures of symptom severity in other obsessive-compulsive and impulse control disorders, such as pathological gambling (PG-YBOCS) [12] and body dysmorphic disorder (BDD-YBOCS) [13] .
On a 6-item scale (range 0–24) patients were asked about the (1) time they spent on misophonia; (2) interference with social functioning; (3) level of anger; (4) resistance against the impulse; (5) control they had over their thoughts and anger; and (6) time they spent avoiding misophonic situations. Scores from 0–4 are considered subclinical misophonic symptoms, 5–9 mild, 10–14 moderate, 15–19 severe, 20–24 extreme.
To rule out any potential hearing problems we randomly selected five patients to perform a standard hearing test, including pure tone, speech audiometry and loudness discomfort levels, which are commonly performed to objectify hearing loss or distortion [14] , [15] . One patient’s test showed unexplained conductive hearing loss. In the other four patients no significant audiological distortion was found and further testing was therefore omitted.
The medical ethics testing committee of the Academic Medical Center did not require approval because this study was anecdotal and observational. All patients gave written informed consent for publication.
The Hamilton Depression Rating Scale (HAM-D) [7] (link), a 17-item scale determining a patient’s level of depression.
The 14-item Hamilton Anxiety Rating Scale (HAM-A) [8] (link), which measures the severity of anxiety symptoms.
The Symptom Checklist (SCL-90) [9] (link), which is a widely used screening instrument for mental and physical dysfunctioning. The 90 items comprise eight subscales: Agoraphobia, Anxiety, Depression, Somatic complaints, Insufficiency in thinking and acting, Suspicion and interpersonal sensitivity, Hostility and Sleep problems. The total score is seen as a general index for psychoneuroticism.
To measure the severity of the misophonia symptoms, we developed an adapted version of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [10] (link), [11] (link), which we have named the Amsterdam Misophonia Scale (A-MISO-S). Similar adaptations of the Y-BOCS have appeared to be reliable and valid measures of symptom severity in other obsessive-compulsive and impulse control disorders, such as pathological gambling (PG-YBOCS) [12] and body dysmorphic disorder (BDD-YBOCS) [13] .
On a 6-item scale (range 0–24) patients were asked about the (1) time they spent on misophonia; (2) interference with social functioning; (3) level of anger; (4) resistance against the impulse; (5) control they had over their thoughts and anger; and (6) time they spent avoiding misophonic situations. Scores from 0–4 are considered subclinical misophonic symptoms, 5–9 mild, 10–14 moderate, 15–19 severe, 20–24 extreme.
To rule out any potential hearing problems we randomly selected five patients to perform a standard hearing test, including pure tone, speech audiometry and loudness discomfort levels, which are commonly performed to objectify hearing loss or distortion [14] , [15] . One patient’s test showed unexplained conductive hearing loss. In the other four patients no significant audiological distortion was found and further testing was therefore omitted.
The medical ethics testing committee of the Academic Medical Center did not require approval because this study was anecdotal and observational. All patients gave written informed consent for publication.
Acclimatization
Agoraphobia
Anger
Anxiety
Audiometry
Audiometry, Speech
Body Dysmorphic Disorders
Conductive Hearing Loss
Diploid Cell
Disruptive, Impulse Control, and Conduct Disorders
Dyssomnias
Epistropheus
Hearing Impairment
Hostility
Hypersensitivity
misophonia
Obsessive-Compulsive Disorder
Patients
Personality Disorders
Physical Examination
Psychiatrist
Respiratory Diaphragm
SCID Mice
Thinking
Vision
Alcohol Use Disorder
Anxiety Disorders
Diagnosis
Disabled Persons
Interviewers
Mood
Nicotine Use Disorder
Personality Disorders
Wounds and Injuries
The present study included 121 healthy volunteers aged 27.22 ± 10.61 years old, and 22 depressed patients aged 29.48 ± 9.28 years old.
This mixed population was chosen because of the nature of the instrument. The STAI principally measures anxiety as a feature of the general population, so the main study sample to test the properties of the instrument should be 'healthy normal subjects'. However it is also important to test the properties of the instrument in a population that manifests higher than normal levels of anxiety. Depressed patients were chosen on the basis that this patients population was easier for the researchers to recruit taking into consideration practical issues.
Patients were physically healthy with normal clinical and laboratory findings (Electroencephalogram, blood and biochemical testing, thyroid function, test for pregnancy, B12 and folic acid). They came from the inpatient and outpatient unit of the 3rd Department of Psychiatry, Aristotle University of Thessaloniki, General Hospital AHEPA, Thessaloniki, Greece. They were consecutive cases and were chosen because they fulfilled the above criteria.
The normal controls group was composed by members of the hospital staff, students and other volunteers. A clinical interview confirmed that they did not suffer from any mental disorder and their prior history was free from mental and thyroid disorder. They were free of any medication for at least two weeks and were physically healthy.
All patients and controls provided written informed consent before participating in the study.
Translation and back translation were made by two of the authors; one of whom did the translation and the other who did not know the original English text did the back translation. The final translation was fixed by consensus of all authors.
The Greek translation along with the translated manual of the test will be available from the same publisher of the English version of the test and manual.
Clinical diagnosis was reached with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) version 2.0 [9 (link),10 ] and the International Personality Disorders Examination (IPDE) [11 (link)-14 (link)]. Both were applied by one of the authors (KNF) who has official training in a World Health Organization Training and Reference Center. The IPDE did not contribute to the clinical diagnosis of anxiety and/or depression, but was used in the frame of a global and comprehensive assessment of the patients. The second examiner performed an unstructured interview. The Symptoms Rating Scale for Depression and Anxiety (SRSDA) which provides an Anxiety index and a Beck Depression Inventory-21 score and the Eysenk Personality Questionnaire (EPQ) were applied for cross-validation purposes.
In 20 of the patients the instrument was re-applied 1–2 days later
This mixed population was chosen because of the nature of the instrument. The STAI principally measures anxiety as a feature of the general population, so the main study sample to test the properties of the instrument should be 'healthy normal subjects'. However it is also important to test the properties of the instrument in a population that manifests higher than normal levels of anxiety. Depressed patients were chosen on the basis that this patients population was easier for the researchers to recruit taking into consideration practical issues.
Patients were physically healthy with normal clinical and laboratory findings (Electroencephalogram, blood and biochemical testing, thyroid function, test for pregnancy, B12 and folic acid). They came from the inpatient and outpatient unit of the 3rd Department of Psychiatry, Aristotle University of Thessaloniki, General Hospital AHEPA, Thessaloniki, Greece. They were consecutive cases and were chosen because they fulfilled the above criteria.
The normal controls group was composed by members of the hospital staff, students and other volunteers. A clinical interview confirmed that they did not suffer from any mental disorder and their prior history was free from mental and thyroid disorder. They were free of any medication for at least two weeks and were physically healthy.
All patients and controls provided written informed consent before participating in the study.
The Greek translation along with the translated manual of the test will be available from the same publisher of the English version of the test and manual.
In 20 of the patients the instrument was re-applied 1–2 days later
Anxiety
BLOOD
Depressive Symptoms
Diagnosis
Electroencephalography
Folic Acid
Healthy Volunteers
Inpatient
Mental Disorders
Outpatients
Patients
Personality Disorders
Personnel, Hospital
Pharmaceutical Preparations
Pregnancy Tests
Reading Frames
Student
Thyroid Diseases
Thyroid Gland
Voluntary Workers
Information on the main psychiatric diagnosis according to the International Classification of Diseases, ICD-10 [27 ] was collected from the patients’ medical records. The diagnoses were grouped into the following binary variables (1 = presence 0 = absence): schizophrenia (F20), other psychoses (F22–F25, F28–F29), bipolar disorders (F31), depression (F32–F33), anxiety (F40, F41), eating disorders (F50), personality disorders (F60, F61), and other psychiatric diagnoses or unspecified (i.e., all other F-diagnoses).
Anxiety Disorders
Bipolar Disorder
Diagnosis
Diagnosis, Psychiatric
Eating Disorders
Mental Disorders
Patients
Personality Disorders
Schizophrenia
Most recents protocols related to «Personality Disorders»
The SUD diagnoses and psychiatric diagnoses according to ICD-10 criteria, were made by a medical specialist or clinical psychologist using standardized clinical interviews and tools.
For the purpose of the current study, information on the dependence-level SUD diagnosis and any co-occurring psychiatric diagnosis was obtained from the medical record. The following binary SUD diagnosis (1 = presence, 0 = absence) were included in analyses: Alcohol use disorder (F10); Opioid use disorder (F11); Cannabis use disorder (F12); Sedatives use disorder (F13); Stimulant use disorder (F15). The psychiatric diagnoses were grouped into the following binary variables (1 = presence, 0 = absence): Mood disorders (F30-F39); Anxiety disorders (F40-F49); Personality disorders (F60-F69); ADHD (F90-F90.0), and other psychiatric diagnoses.
For the purpose of the current study, information on the dependence-level SUD diagnosis and any co-occurring psychiatric diagnosis was obtained from the medical record. The following binary SUD diagnosis (1 = presence, 0 = absence) were included in analyses: Alcohol use disorder (F10); Opioid use disorder (F11); Cannabis use disorder (F12); Sedatives use disorder (F13); Stimulant use disorder (F15). The psychiatric diagnoses were grouped into the following binary variables (1 = presence, 0 = absence): Mood disorders (F30-F39); Anxiety disorders (F40-F49); Personality disorders (F60-F69); ADHD (F90-F90.0), and other psychiatric diagnoses.
Alcohol Use Disorder
Anxiety Disorders
Cannabis
Diagnosis
Diagnosis, Psychiatric
Disorder, Attention Deficit-Hyperactivity
Mood Disorders
Opioid Use Disorder
Personality Disorders
Psychologist
Sedatives
Statistical analysis included descriptive statistics for the prevalence of co-occurring psychiatric diagnoses in the total sample, and according to types of SUD diagnoses. We compared the characteristics of patients with - and without COD using proportion tests and independent samples t-tests. The prevalence of types of CODs was examined for the following psychiatric disorders: anxiety (F40-F49); mood (F30-39), ADHD (F90-90.9); personality disorder (F60-69); multiple CODs. Gender differences in the prevalence of each types of CODs were examined using bivariate logistic regression analysis. Bivariate logistic regression analyses were also undertaken to investigate factors associated with relapse. Repeated-measures generalized logistic mixed modeling (GLMM) with a diagonal covariance matrix was used to assess the multivariate association of demographic (age, gender, education), psychological (motivation, mental distress) and types of SUD diagnoses with relapse at 3 month follow-up. The analysis accounted for the prospective nested nature of the data structure (i.e., the same patients nested over time). Since mental distress was measured at two time points (baseline and follow-up), this variable was entered as a time-varying covariate accounting for variation in mental distress across the study period. Variables indicating the center where the patients were treated (unit 1–5) and the length of stay (number of days) were included in the multivariate models to control for any treatment- related differences in relapse rates. We did not incorporate the treatment center variable as a random effect in the analysis due to the small number of patients at each treatment center, which made it complicated to account for the variance of treatment center as a random effect due to the substantial risk of Type II error. The variance inflation factors were < 2 for all independent variables, indicating that multicollinearity was not a concern [35 ]. We ran the GLMM analyses separately for patients with and without COD. SPSS 28 was used for statistical analyses.
Anxiety
Cods
Diagnosis
Diagnosis, Psychiatric
Disorder, Attention Deficit-Hyperactivity
Gender
Mental Disorders
Mood
Motivation
Patients
Personality Disorders
Relapse
Respiratory Diaphragm
The proportion of patients with COD was not significantly different for male (45.4%) and female (52.0%) patients (p = 0.139). The prevalence rates for the types of co-occurring psychiatric diagnoses are shown in Table 2 . Among patients with COD, anxiety (22.9%) and mood disorders (17.3%) were the two most common psychiatric disorders. About one in five had more than one COD (21.4%), with a higher prevalence rate of multiple CODs among females (30.3%) than males (18.0%). Having anxiety disorders were significantly more prevalent among females (30.3%) than males (19.8%).
Prevalence of co-occurring psychiatric disorders
| Total | Females | Males | Females versus malesref | |||||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | OR | p-value | |
| Without COD | 322 | 52.7 | 84 | 48.0 | 237 | 54.6 | ||
| With COD | 289 | 47.3 | 91 | 52.0 | 197 | 45.4 | 1.30 | 0.139 |
| Psychiatric diagnoses1 | ||||||||
| - Anxiety disorders F40-49 | 140 | 22.9 | 53 | 30.3 | 86 | 19.8 | 1.76 | |
| - Mood disorders F30-39 | 106 | 17.3 | 36 | 20.6 | 70 | 16.1 | 1.35 | 0.191 |
| - ADHD F90.0-F90.9 | 79 | 12.9 | 21 | 12.0 | 58 | 13.4 | 0.88 | 0.650 |
| - Personality disorders F60-69 | 70 | 11.5 | 27 | 15.4 | 43 | 9.9 | 1.66 | 0.053 |
| - Multiple CODs | 131 | 21.4 | 53* | 30.3 | 78 | 18.0 | 1.98 | |
1 Other psychiatric diagnoses (n = 17) included Schizophrenia, F20-F29 (n = 8); Behavioral syndromes associated with physiological disorders and physical factors (n = 16); Mental retardation, F70-F79 (n = 6); Pervasive and specific developmental disorders, F80-89 (n = 16); Behavioral disorders, F91-F98 (n = 8)
Anxiety Disorders
Behavior Disorders
Cods
Developmental Disabilities
Diagnosis, Psychiatric
Disorder, Attention Deficit-Hyperactivity
Females
Intellectual Disability
Males
Mental Disorders
Mood
Mood Disorders
Patients
Personality Disorders
Physical Examination
physiology
Schizophrenia
Syndrome
Woman
After the last 18-month follow-up, the study dataset will be sent to Statistics Denmark with a list of all invited participants to allow a non-participant analysis and long-term follow-up. The study data will be linked with data from the Danish Civil Registration System [76 (link)] e.g., the DNPR [57 (link)], the Danish National Prescription Registry [55 (link), 56 ], and other registries indexing, e.g., hospital admittance, diagnosis- and treatment codes, prescription medications, employment status, living situation (e.g., partner information), and income. We will also examine diagnostic stability [77 (link)], e.g., change of primary diagnosis from first episode depression to an anxiety or personality disorder or later recurrent depressive episode or conversion to bipolar affective disorder.
Anxiety Disorders
Diagnosis
Disorder, Dissociative
Personality Disorders
Prescription Drugs
Participants ranged in age from 25 to 58 (mean age 41). Their current living situation was reported as either currently homeless (38%), supported housing (50%), private rented accommodation (6%) and 6% were vulnerably housed in unsuitable accommodation.
Primary presenting substance misuse was reported as opiates (74%), alcohol (13%), and benzodiazepines (13%). Self-identified poor mental health was characterised as suffering from long term depression and anxiety, and 100% had trouble sleeping. 63% of participants reported suicidal ideation within the past 12 months. 25% reported that they had ever been admitted to a psychiatric facility. A minority had psychiatric diagnoses (6%) which were reported as schizophrenia and personality disorder.
Within the previous 12 months, 56% had accessed housing support services, 56% had used substance misuse services, 38% had accessed support for domestic abuse and 25% had accessed mental health support. Fifty percent had visited their GP at least once. Significant acute healthcare use was reported, with at least 18 individual admissions to A&E reported within the group in the previous 12 months.
Primary presenting substance misuse was reported as opiates (74%), alcohol (13%), and benzodiazepines (13%). Self-identified poor mental health was characterised as suffering from long term depression and anxiety, and 100% had trouble sleeping. 63% of participants reported suicidal ideation within the past 12 months. 25% reported that they had ever been admitted to a psychiatric facility. A minority had psychiatric diagnoses (6%) which were reported as schizophrenia and personality disorder.
Within the previous 12 months, 56% had accessed housing support services, 56% had used substance misuse services, 38% had accessed support for domestic abuse and 25% had accessed mental health support. Fifty percent had visited their GP at least once. Significant acute healthcare use was reported, with at least 18 individual admissions to A&E reported within the group in the previous 12 months.
Anxiety
Benzodiazepines
Diagnosis, Psychiatric
Drug Abuse
Ethanol
Mental Health
Minority Groups
Ocular Accommodation
Opiate Alkaloids
Personality Disorders
Persons, Homeless
Schizophrenia
Top products related to «Personality Disorders»
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Spain, France, Denmark, Switzerland, Ireland
SPSS version 20 is a statistical software package developed by IBM. It provides a range of data analysis and management tools. The core function of SPSS version 20 is to assist users in conducting statistical analysis on data.
Sourced in United States, Denmark, United Kingdom, Belgium, Japan, Austria, China
Stata 14 is a comprehensive statistical software package that provides a wide range of data analysis and management tools. It is designed to help users organize, analyze, and visualize data effectively. Stata 14 offers a user-friendly interface, advanced statistical methods, and powerful programming capabilities.
Sourced in United States, Japan, Germany, United Kingdom, Belgium, Austria, Spain
SPSS Statistics 24 is a software package used for statistical analysis. It provides a comprehensive set of tools for data management, analysis, and presentation. The software is designed to handle a wide range of data types and offers a user-friendly interface for conducting various statistical procedures.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States, Japan, United Kingdom, Germany, Austria, Canada, Belgium, Spain
SPSS version 26 is a statistical software package developed by IBM. It is designed to perform advanced statistical analysis, data management, and data visualization tasks. The software provides a wide range of analytical tools and techniques to help users understand and draw insights from their data.
Sourced in United States, Germany, United Kingdom, Belgium, Japan, China, Austria, Denmark
SPSS v20 is a statistical software package developed by IBM. It provides data management, analysis, and visualization capabilities. The core function of SPSS v20 is to enable users to perform a variety of statistical analyses on data, including regression, correlation, and hypothesis testing.
Sourced in United States, United Kingdom, Japan, Germany, Austria, Belgium, France, Denmark
SPSS 24.0 is a statistical software package developed by IBM. It provides data management, analysis, and reporting capabilities. The software is designed to handle a wide range of data types and is commonly used for social science research, market research, and business analytics.
Sourced in United States, United Kingdom
Stata/MP 14.0 is a powerful data analysis and statistical software package developed by StataCorp. It is designed to handle large and complex datasets, providing efficient parallel processing capabilities to accelerate computations. Stata/MP 14.0 offers a comprehensive suite of statistical tools and modeling techniques, enabling users to analyze, visualize, and interpret their data effectively.
Sourced in United States
STATA version 13 for Windows is a statistical software package developed by StataCorp. It provides a comprehensive set of tools for data management, analysis, and visualization. STATA version 13 offers a range of features and functionalities to support various research and analytical tasks.
More about "Personality Disorders"
Personality Disorders are a group of mental health conditions characterized by rigid and maladaptive patterns of thought, emotion, and behavior that deviate from cultural norms.
These disorders can significantly impair an individual's ability to function in social, occupational, and personal relationships.
Effective research and treatment of Personality Disorders is crucial for improving quality of life and reducing the burden on individuals, families, and healthcare systems.
PubCompare.ai can help optimize your Personality Disorders research by locating the best protocols from literature, preprints, and patents using AI-driven comparisons to enhance reproducibility and accuracy.
Leverage our tool to identify the most effective products and protocols for your Personality Disorders studies and experience the power of data-driven insights today.
Subtopics related to Personality Disorders include: - Cluster A Personality Disorders (e.g., Paranoid, Schizoid, Schizotypal) - Cluster B Personality Disorders (e.g., Antisocial, Borderline, Histrionic, Narcissistic) - Cluster C Personality Disorders (e.g., Avoidant, Dependent, Obsessive-Compulsive) - Personality Disorder Not Otherwise Specified (PDNOS) - Comorbidity with other mental health conditions (e.g., depression, anxiety, substance abuse) - Personality Disorder assessment and diagnosis (e.g., clinical interviews, self-report measures, diagnostic criteria) - Personality Disorder treatment approaches (e.g., psychotherapy, medication, combination therapy) Researchers can leverage statistical software such as SAS version 9.4, SPSS version 20, Stata 14, SPSS Statistics 24, SAS 9.4, SPSS version 26, SPSS v20, SPSS 24.0, Stata/MP 14.0, and STATA version 13 for Windows to analyze data and inform their Personality Disorders studies.
These tools can help identify patterns, trends, and statistical significance within Personality Disorders research data.
These disorders can significantly impair an individual's ability to function in social, occupational, and personal relationships.
Effective research and treatment of Personality Disorders is crucial for improving quality of life and reducing the burden on individuals, families, and healthcare systems.
PubCompare.ai can help optimize your Personality Disorders research by locating the best protocols from literature, preprints, and patents using AI-driven comparisons to enhance reproducibility and accuracy.
Leverage our tool to identify the most effective products and protocols for your Personality Disorders studies and experience the power of data-driven insights today.
Subtopics related to Personality Disorders include: - Cluster A Personality Disorders (e.g., Paranoid, Schizoid, Schizotypal) - Cluster B Personality Disorders (e.g., Antisocial, Borderline, Histrionic, Narcissistic) - Cluster C Personality Disorders (e.g., Avoidant, Dependent, Obsessive-Compulsive) - Personality Disorder Not Otherwise Specified (PDNOS) - Comorbidity with other mental health conditions (e.g., depression, anxiety, substance abuse) - Personality Disorder assessment and diagnosis (e.g., clinical interviews, self-report measures, diagnostic criteria) - Personality Disorder treatment approaches (e.g., psychotherapy, medication, combination therapy) Researchers can leverage statistical software such as SAS version 9.4, SPSS version 20, Stata 14, SPSS Statistics 24, SAS 9.4, SPSS version 26, SPSS v20, SPSS 24.0, Stata/MP 14.0, and STATA version 13 for Windows to analyze data and inform their Personality Disorders studies.
These tools can help identify patterns, trends, and statistical significance within Personality Disorders research data.